Last Price
4.12
Today's Change
-0.17 (3.96%)
Day's Change
3.99 - 4.33
Trading Volume
356,125
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. William J. Newell J.D. Mr. William J. Newell J.D.
Full Time Employees: 304 304
IPO Date: 2018-09-27 2018-09-27
CIK: 0001382101 0001382101
ISIN: US8693671021 US8693671021
CUSIP: 869367102 869367102
Beta: 1.18 1.18
Last Dividend: 0.00 0.00
Dcf Diff: 4.32 4.32
Dcf: -0.14 -0.14
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.